65,437 trials
Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 0; 1; 13; 3 participants
Hemophilia A
Primary: Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIII — 0; 0 Participants
Gastroparesis · Dyspepsia
Primary: Gastric Emptying Half-time (T1/2) of Solids — 128.7; 125.8; 246.4; 198.4 minutes
NICU MRI
Primary: Number of Participants With Adverse Events as Observed During and After Scanning. — 0 Participants
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
HIV Infections
Primary: Frequency of Grade 3 or Higher Adverse Events — 0 number of occurrences
Epistaxis
Primary: Number of Participants With Epistaxis — 11; 2 Participants
Attention-Deficit/Hyperactivity Disorder
Primary: Incidence of Adverse Events — 72.3 percentage of subjects
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Among Participants Administered V110 — 18.7; 14.7; 74.8; 74.4 Percentage of Participants
Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Change in Quality of Life — 0.37; -0.17; 0.43; -0.08 score on a scale
Parkinson Disease
Primary: Tremor Power — 64 Percentage of tremor power reduction
Glenohumeral Joint Degeneration
Primary: Active Forward Elevation of the Shoulder — 146; 141; 143; 137 degrees of movement — p=.552
Hypothalamic Injury-induced Obesity (HIO)
Primary: Number of Participants With Treatment Emergent Adverse Events — 12; 7 Participants
Type1diabetes
Primary: Time to Maximum Glucose Infusion Rate — 116.54; 172.21 minutes
Neoplasms
Primary: Part 1A: Number of Participants Experiencing Dose Limiting Toxicity (DLT) — 0; 1; 0; 0 Participants